Crohn’s disease drugmakers to benefit from expected rise in cases

Pharmaceutical companies that market drugs for Crohn’s disease — or have ones in development — are poised to benefit from an expected rise in cases of the inflammatory bowel disease.

As of 2022, there were 1.63M cases of Crohn’s in eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Canada). The number is projected to rise to 1.69M by 2032, according to analysis and consulting firm GlobalData.